ImmunoEdge is advancing the discovery of tumor-derived immune targets.
We’ve developed a novel peptide capture technology that improves detection of HLA-presented peptides — revealing a broader and more immunologically relevant landscape, especially from low-input tumor biopsies.
Many promising immune targets are currently missed due to limitations in standard methods. By increasing visibility into this hidden layer of tumor biology, ImmunoEdge supports better target discovery, TCR design, and the development of next-generation immunotherapies.
We are guided by a Scientific Advisory Board including Prof. Oreste Acuto (Oxford), a leading expert in T-cell signaling, and Dr. Christophe Masselon (CEA), specialist in mass spectrometry instrumentation and bioanalytical methods.
Company Details
- Founded
- -
- Address
- Heidelberg, Bwb 69121, De
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://www.immunoedge.de/
- Keywords
- Peptide Capture Technology, Immunopeptidomics, Tumor Immunology, Neoepitope Discovery, Low-Input Biopsy Analysis, HLA-Peptide Profiling, Cancer Target Identification, Biotech Innovation.
- HQ
- Heidelberg, BWB
Immunoedge Questions
Immunoedge's website is https://www.immunoedge.de/
Immunoedge's LinkedIn profile is https://de.linkedin.com/company/immunoedge
Immunoedge's industry is
Hospitals and Health Care
Immunoedge's top competitors are
Artpass,
Togethina,
Contextml Ug (Haftungsbeschränkt),
Solhyd Energy Gmbh,
Resonate Bio,
Qlyros,
Blocktracts,
Re:yve,
Bridgelatam,
Ms Scientific Consulting.
Immunoedge's categories are Hospitals and Health Care
Immunoedge's founding year is 2024
